NCT04951219Phase 3Active not recruiting

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03Estimated

Enrollment · participants810Actual

Source updated2026-05-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-27 · 3 fields changed

Participant count type

Recorded edit

− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit

− Previous value

count: 1000; type: ESTIMATED

+ Updated value

count: 810; type: ACTUAL

Primary completion date

Recorded edit

− Previous value

2026-03

+ Updated value

2027-03

Check registry source